Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.30 EUR
Change Today -0.139 / -2.56%
Volume 150.8K
ECX On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Xetra
As of 3:35 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

epigenomics ag (ECX) Snapshot

Open
€5.50
Previous Close
€5.44
Day High
€5.55
Day Low
€5.20
52 Week High
05/6/14 - €7.27
52 Week Low
06/3/14 - €2.80
Market Cap
84.2M
Average Volume 10 Days
57.2K
EPS TTM
€-0.74
Shares Outstanding
15.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPIGENOMICS AG (ECX)

Related News

No related news articles were found.

epigenomics ag (ECX) Related Businessweek News

No Related Businessweek News Found

epigenomics ag (ECX) Details

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer, which relies on its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung BL Reflex Assay, a confirmatory test that aids in the diagnosis of lung cancer. Its development pipeline also contains tests for screening, monitoring, diagnosis, and prognosis assessment in colorectal, lung, and prostate cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

37 Employees
Last Reported Date: 03/25/15
Founded in 1998

epigenomics ag (ECX) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: €288.8K
Chief Operating Officer and Member of Executi...
Total Annual Compensation: €177.2K
Compensation as of Fiscal Year 2013.

epigenomics ag (ECX) Key Developments

Epigenomics AG Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 01:40 PM

Epigenomics AG Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Epigenomics AG Announces Completion of Enrollment in Epi ProColon(R) ADMIT Trial

Epigenomics AG announced the completion of subject enrollment into it’s ADMIT trial (ADherence to Minimally Invasive Testing - NCT02251782) for its non-invasive blood-based test for colorectal cancer (CRC) screening, Epi proColon(R). The company expects to announce results from this study during the second quarter of 2015. The company has successfully completed enrollment in the ADMIT clinical trial this week. Study subjects were identified as historically non-compliant to CRC screening according to current screening guidelines by its partners, Kaiser Permanente and Geisinger Health Systems, who actively manage CRC screening programs in the U.S.A. Subjects were invited to a clinic visit and once enrolled into the trial, were randomized to either the FIT test to take home to complete and send back within six weeks, or to a blood draw for the Epi proColon(R) test, to be completed in the same time frame. The trial was requested by the US Food and Drug Administration (FDA) in the context of Epigenomics' pre-market approval (PMA) application for Epi proColon(R). It was designed to compare adherence to CRC screening in subjects offered blood-based testing with Epi proColon(R) to stool-based testing with a fecal immunochemical test (FIT), a guideline recommended method. The primary endpoint is a statistically significant increase in adherence to testing by subjects offered the Epi proColon(R) test compared to subjects given the FIT test. The study's secondary objectives include a measurement of compliance to colonoscopy in subjects with positive result for either test. Trial results will be submitted to the FDA following data analysis after completion of the six week response window.

Epigenomics AG Reports Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Epigenomics AG reported earnings results for the year ended December 31, 2014. For the year, the company’s total revenue amounted to EUR 1.5 million against EUR 1.6 million a year ago. The slight decrease compared to the previous year was mainly due to the phase out of some existing licensing agreements ahead of the expected approval of the Epi proColon(R) test kit for commercialization in the U.S.A. On this basis operating loss (EBIT) in 2014 widened to EUR 8.4 million against EUR 7.3 million a year ago. Due to non-cash interest expenses in the amount of EUR 0.5 million for the convertible bond program, net loss increased to EUR 8.9 million against EUR 7.4 million a year ago. This equals a loss per share of EUR 0.65 against EUR 0.62 a year ago. For 2015, the company expects revenue to be in the range of EUR 3.0 million to EUR 4.0 million with the bulk of this in the second half of the year. This assumes the approval of Epi proColon(R) in the U.S.A. around the middle of 2015. This growth in revenue is almost exclusively driven by the expected initial product sales in the U.S.A. and in China. EBIT loss for 2015 is expected to be at a lower level than in 2014 at EUR 10.0 million to EUR 11.0 million. Efforts to develop the U.S. market for the company's lead product will initially hinder the operating result. In addition, expenditures in connection with the current ADMIT trial, as well as a post-approval study expected to be mandated as part of the FDA approval in the second half of 2015, will also be contributing factors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECX:GR €5.30 EUR -0.139

ECX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECX.
View Industry Companies
 

Industry Analysis

ECX

Industry Average

Valuation ECX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIGENOMICS AG, please visit www.epigenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.